Navidea Biopharmaceuticals opens Boston commercialization office
Employees at Navidea’s new Andover, Massachusetts office will focus much of their attention on the expected launch later this year of drug candidate Lymphoseek, a targeting agent used by surgeons to identify lymph nodes in patients with breast cancer or melanoma and to indicate whether cancer has spread to a particular lymph node.
Lymphoseek is in the midst of a review by the U.S. Food and Drug Administration and could be approved for sales and marketing as soon as this summer.
Navidea’s corporate headquarters, with clinical, manufacturing, regulatory and administration functions, will remain in Dublin, Ohio, according to a statement from the company.
Navidea, which until earlier this year was known as Neoprobe, is also working toward European commercialization of Lymphoseek and last week reported obtaining “positive guidance” from regulators about a path forward for the drug.
The company plans by the end of the year to submit regulatory documents aimed at securing European marketing approval of Lymphoseek.
[Photo from flickr user Manu_H]